Steven Altschuler - Spark Therapeutics Chairman of the Board
Chairman
Dr. Steven M. Altschuler, M.D. is Independent Chairman of the Board of Spark Therapeutics, Inc. Dr. Altschuler was serving as an Academic Healthcare Consultant working with multiple health systems since October 2017. He was serving as a Managing Director at Ziff Capital Partners since May 2018. He served as the Executive Vice President of Health Affairs at the University of Miami and Chief Executive Officer of UHealthUniversity of Miami Health System from January 2016 to October 2017. Previously, he was Chief Executive Officer of CHOP and The Childrens Hospital of Philadelphia Foundation, or the CHOP Foundation, from April 2000 to November 2015. Prior to serving as the Chief Executive Officer of CHOP, Dr. Altschuler served in many leadership roles at CHOP including Division Chief of Gastroenterology, PhysicianinChief, inaugural holder of the Leonard and Madlyn Abramson Endowed Chair in Pediatrics and Professor and Chair of the Department of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, where he was a faculty member from 1985 to 2000. Dr. Altschuler served on the board of directors for Mead Johnson Nutrition Company from 2009 through 2017. Dr. Altschuler currently is chair of the Compensation and Audit Committees and has served on the board of directors of Weight Watchers International since 2012. Dr. Altschuler has served on the Board of Adtalem Global Education Inc. since May 2018 and is a member of its Audit and Finance Committee and Academic Quality Committee since 2013.
| Age | 64 |
| Tenure | 11 years |
| Phone | 888 772-7560 |
| Web | www.sparktx.com |
Spark Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.107) % which means that it has lost $0.107 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1515) %, meaning that it created substantial loss on money invested by shareholders. Spark Therapeutics' management efficiency ratios could be used to measure how well Spark Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 138.01 M in liabilities with Debt to Equity (D/E) ratio of 34.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Spark Therapeutics has a current ratio of 5.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Spark Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Spark Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Spark Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Spark to invest in growth at high rates of return. When we think about Spark Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 6 records | CHAIRMAN Age | ||
| Yongjie Liu | Yuexiu Transport Infrastructure | 57 | |
| Chunxiu Zhu | Yuexiu Transport Infrastructure | 52 | |
| Hans Aas | SFL Corporation | 70 | |
| Yossef Lahad | BOS Better Online | 58 | |
| Youpan Liang | Yuexiu Transport Infrastructure | 58 | |
| Shenglong Zou | Xunlei Ltd Adr | 41 | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.11 |
Spark Therapeutics Leadership Team
Elected by the shareholders, the Spark Therapeutics' board of directors comprises two types of representatives: Spark Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spark. The board's role is to monitor Spark Therapeutics' management team and ensure that shareholders' interests are well served. Spark Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spark Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Romuald Corbau, Translational Research Lead | ||
| Carol GrevePhilips, Head of Business Development and Strategy | ||
| Robert Perez, Director | ||
| Lars Ekman, Independent Director | ||
| Jennifer Wellman, Co-Founder and Head of Regulatory Strategy | ||
| Fraser Wright, Co-Founder and CTO | ||
| Morgan Molloy, Head of U.S. Commercial | ||
| Lorris Betz, Director | ||
| Joseph Barge, General Counsel and Head of Business Administration | ||
| Katherine High, President Chief Scientific Officer, Director | ||
| Elliot Sigal, Independent Director | ||
| John Furey, COO | ||
| Vincent Milano, Independent Director | ||
| Lota Zoth, Director | ||
| Rogerio Coelho, Chief Commercial Officer | ||
| Elliott Sigal, Independent Director | ||
| Guang Qu, Head of Process Development | ||
| Daniel Takefman, Head of Regulatory Affairs | ||
| Stephen Webster, CFO | ||
| Rogerio Vivaldi, Chief Commercial Officer | ||
| Diane Blumenthal, Head of Technical Operations | ||
| Jeffrey Marrazzo, CEO, Co-Founder, Director | ||
| Daniel Faga, Chief Business Officer | ||
| Anand Mehra, Independent Director | ||
| Linda Hearne, Financial Operations and Analysis Lead | ||
| Paul Gil, Regulatory CMC and Quality Assurance Lead | ||
| Charles Sigal, Independent Director | ||
| Federico Mingozzi, Chief Scientific Officer | ||
| Steven Altschuler, Chairman of the Board | ||
| Lisa Dalton, Head - Human Resources |
Spark Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spark Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (0.0009) % | |||
| Current Valuation | 3.97 B | |||
| Shares Outstanding | 38.49 M | |||
| Shares Owned By Insiders | 7.45 % | |||
| Shares Owned By Institutions | 92.25 % | |||
| Number Of Shares Shorted | 3.47 M | |||
| Price To Earning | (13.29) X | |||
| Price To Book | 10.71 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Spark Therapeutics information on this page should be used as a complementary analysis to other Spark Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Spark Stock
If you are still planning to invest in Spark Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spark Therapeutics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |